564 results on '"Hogge, Donna E."'
Search Results
102. Novel Photodepletion Strategy to Preserve and Expand Tregs While Eliminating CD4+ Effector T Cells From Patients with Chronic Graft-Versus-Host Disease
103. Phase IIB Randomized Study of CPX-351 Versus Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: An Interim Analysis
104. Characterization of variant diphtheria toxin–interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials
105. High Incidence of Invasive Fungal Infections in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation.
106. CD34, CD56 and CD2 Are Predictive of NPM1 Mutation, FLT3-ITD and Their Favorable Prognosis Combination in Cytogenetically Normal Acute Myeloid Leukemia.
107. Short Progression Free Survival Post Non-Myeloablative Sibling Allogeneic Stem Cell Transplantion for Multiple Myeloma.
108. Differential Expression of Mirna* Species in Cancer and the Contribution of MiR-223* to the Development of Acute Myeloid Leukemia.
109. Improved Selectivity against Acute Myeloid Leukemia (AML) Blasts Over Normal Hematopoietic Progenitors for Cytarabine: Daunorubicin Delivered as CPX-351 Liposome Injection.
110. Exposure to Novel Agents Increases Post Relapse Survival in Patients with High Risk Myeloma Defined by Early Relapse (<12 months).
111. Distinct Signaling Profiles of Gemtuzumab Ozogamicin Responsiveness and Refractoriness in Acute Myeloid Leukemia.
112. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia
113. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells
114. QLT0267, a Small Molecule Inhibitor of ILK and FLT3 Is Cytotoxic to Acute Myeloid Leukemia (AML) ‘Stem Cells’ Detected in Immunodeficient Mice.
115. Impact of Comorbidity Index on Outcome with Allogeneic Hematopoetic Stem Cell Transplantation for Chronic Lymphocytic Leukemia
116. Identification of Mir-145 and Mir-146a as Micrornas Involved in the Pathogenesis of 5q- Syndrome
117. Autologous Stem Cell Transplantation Is Superior to Myeloablative Allogeneic SCT as a Salvage Therapy for Patients with Refractory/Relapsed Transformed Lymphoma
118. Comparison of Outcome Between Refractory/Relapsed De Novo Diffuse Large B-Cell and Transformed Lymphoma Using Related and Unrelated Allogeneic Hematopoietic SCT.
119. Salvage Therapy with Allogeneic Stem Cell Transplantation Results in Better Outcome for Patients with Relapsed/Refractory Follicular Lymphoma Compared to Those with Transformed Non-Hodgkin Lymphoma: A Population-Based Comparative Study.
120. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia
121. Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.
122. Allogeneic Stem Cell Transplant in First Complete Remission Overcomes the Poor Prognosis Associated with the FLT-3 Internal Tandem Duplication in Acute Myeloid Leukemia.
123. Phase I Study Demonstrates Activity and Tolerability of Diphtheria Toxin Interleukin-3 Fusion Protein in Patients with AML and MDS.
124. Allogeneic Stem Cell Transplantation as Treatment for Relapsed and High-Risk Peripheral T-Cell Lymphoma.
125. Stem Cell Transplantation (SCT) Improves Survival in Acute Biphenotypic (ABL) and Acute Undifferentiated Leukemia (AUL): A Single Centre Experience.
126. Higher CD 34 Cell Doses Reduce Non Relapse Mortality (NRM) and Do Not Increase the Incidence of Graft Versus Host Disease (GVHD) Following Unrelated Donor Blood Stem Cell Transplantation (SCT).
127. High Expression of MDR1 and BCRP1 in Leukemic Stem Cells Correlates with Reversible Drug Resistance Ex Vivo and Predicts Failure of Remission Induction Chemotherapy in Patients with Acute Myeloid Leukemia.
128. Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality.
129. Induction Therapy with High-Dose Dex Alone in Newly Diagnosed Myeloma Patients Produces a 57% Partial Response and Is Predictive of Progression Free Survival.
130. Integrin Linked Kinase Is Expressed in Acute Myeloid Leukemia Blasts and Its Inhibition Is Cytotoxic to Leukemic Progenitors.
131. Prior Rituximab Reduces Relapse and Improves Survival Following High Dose Chemotherapy and Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.
132. Long Term Results of Myeloablative Allogeneic Stem Cell Transplantation Using Related and Unrelated Donors in Patients with Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.
133. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice
134. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.
135. Second Solid Cancers after Allogeneic Stem Cell Transplantation: The Vancouver Experience.
136. Long-Term Follow-Up Results of Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL)-The Vancouver Experience.
137. Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission
138. Long-Term Results of Allogeneic Hematopoietic Stem Cell Transplantation Using Unrelated or HLA Mismatched Family Donors for Acute and Chronic Lymphoid Malignancy.
139. Septicemia in Chemotherapy Induced Neutropenic Acute Myeloid Leukemia (AML) Inpatients and Outpatients: A 5 Year Retrospective Experience.
140. Risk Stratification in Acute Promyelocytic Leukemia Based on Elevated White Cell Count and Reduced Platelet Count Does Not Identify Subsequent Relapses: A Retrospective Review of 60 Patients.
141. Acceptable Outcomes for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) for Relapsed Aggressive Non-Hodgkin’s Lymphoma (NHL).
142. Variant Forms of Human Interleukin-3 (IL-3) Linked to Truncated Diphtheria Toxin (DT388), Have Enhanced Cytotoxicity Against Acute Myeloid Leukemia (AML) Progenitors.
143. Expression of the Human ATP-Binding Cassette Transporter Superfamily in Acute Myeloid Leukemia.
144. High Risk AML Outpatient Management: A Retrospective Analysis of Bacteremia Incidence Following Chemotherapy.
145. Philadelphia-Negative Clonal Hematopoiesis Following Imatinib Therapy in Patients with Chronic Myeloid Leukemia (CML).
146. Salvage of Primary Refractory Acute Leukemia (AL) with High-Dose Etoposide (VP) and Cyclophosphamide (CY) Followed by Early Stem Cell Transplantation (SCT): An Effective Treatment Strategy for AML but Not for All.
147. Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphobastic Lymphoma (T-LBL) : An Intention to Treat Analysis.
148. Daclizumab Therapy Improves Outcome in Steroid Refractory Acute Graft Versus Host Disease (aGVHD).
149. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials
150. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.